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Autotaxin (ATX) is a secreted protein with lysophos-
pholipase D activity that generates lysophosphatidic
acid (LPA) from lysophosphatidylcholine. Here we
report that functional ATX is selectively expressed in
high endothelial venules (HEVs) of both lymph nodes
and Peyer’s patches. ATX expression was develop-
mentally regulated and coincided with lymphocyte
recruitment to the lymph nodes. In adults, ATX ex-
pression was independent of HEV-expressed chemo-
kines such as CCL21 and CXCL13, innate immunity
signals including those via TLR4 or MyD88, and of the
extent of lymphocyte trafficking across the HEVs.
ATX expression was induced in venules at sites of
chronic inflammation. Receptors for the ATX enzyme
product LPA were constitutively expressed in HEV
endothelial cells (ECs). In vitro , LPA induced strong
morphological changes in HEV ECs. Forced ATX ex-
pression caused cultured ECs to respond to lysophos-
phatidylcholine, up-regulating lymphocyte binding
to the ECs in a LPA receptor-dependent manner under
both static and flow conditions. Although in vivo de-
pletion of circulating ATX did not affect lymphocyte
trafficking into the lymph nodes, we surmise, based
on the above data, that ATX expressed by HEVs acts
on HEVs in situ to facilitate lymphocyte binding to
ECs and that ATX in the general circulation does not
play a major role in this process. Tissue-specific inac-
tivation of ATX will verify this hypothesis in future
studies of its mechanism of action. (Am J Pathol 2008,
173:1566–1576; DOI: 10.2353/ajpath.2008.071153)
Much of the efficiency of the immune system depends on
continual lymphocyte recirculation through the second-
ary lymphoid tissues. Lymphocyte recirculation begins
with blood lymphocytes interacting with the endothelial
wall of high endothelial venules (HEVs) in lymph nodes
(LNs) and Peyer’s patches (PPs), in a process called
lymphocyte rolling. The rolling brings lymphocytes into
contact with HEV endothelial cells (ECs), which express a
variety of chemokines and adhesion molecules. Lympho-
cytes bind to these molecules and transmigrate through
the HEVs.1,2 This interaction between lymphocytes and
the molecules on HEV ECs is transient and reversible,
and both lymphocytes and HEV ECs show marked and
coordinated morphological changes during the pro-
cess,3 indicating that each of the two cell types acts on
the other. The molecular details behind these interac-
tions, however, remain to be fully elucidated.
Accumulating evidence indicates that a variety of ly-
sophospholipids act on immune cells by transmitting sig-
nals through a family of G-protein-coupled receptors to
control the cells’ differentiation, motility, and survival.4 In
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particular, structurally related lysophospholipid media-
tors such as sphingosine-1-phosphate (S1P) and lyso-
phosphatidic acid (LPA), which can be generated from
lipid stores by cellular enzymatic pathways in macro-
phages, dendritic cells, mast cells, and platelets, act on
lymphocytes and dendritic cells through members of the
S1P-receptor family (S1P1  S1P5) and the LPA-receptor
family (LPA1  LPA5), respectively.
4–7 Among these li-
gand-receptor interactions, S1P and its receptor S1P1
are required for thymocyte emigration8 as well as lym-
phocyte egress from the secondary lymphoid tissues,9,10
although exactly where and how these signaling mole-
cules function is not fully understood. In addition, the
functional significance of the interaction between LPA
and its receptors in the immune system is unknown.
Autotaxin (ATX), originally identified as a tumor motility-
stimulating protein,11 is a secreted protein identical to
lysophospholipase D (lysoPLD).12 In vitro, ATX converts
lysophosphatidylcholine (LPC) and sphingosylphospho-
rylcholine to LPA12 and S1P,13 respectively. However, a
recent study indicates that ATX is a major producer of
LPA, but not of S1P, in vivo.14 Under physiological con-
ditions, ATX is expressed in the central nervous system
and is implicated in oligodendrocyte function.15 In addi-
tion, ATX transcripts have been found in human tonsillar
HEVs,16 but its protein expression has not been reported
in HEVs, let alone its function. While this manuscript was
under review, Kanda and colleagues17 published that
ATX is involved in lymphocyte trafficking from blood into
lymphoid tissues.
Here we report that ATX is preferentially expressed in
the HEVs of mouse LNs and PPs and that its expression
correlates positively with the ability of venules to support
lymphocyte trafficking across the endothelial walls. ATX
was clearly inducible in chronically inflamed venules that
mediate pathological lymphocyte trafficking. Interest-
ingly, LPA receptors were expressed in HEV ECs, and the
addition of LPA caused substantial cytoskeletal changes.
Forced ATX expression made cultured ECs reactive to
LPC, which up-regulated lymphocyte binding to the ECs
in a LPA receptor-dependent manner. Because ATX is a
major producer of LPA, these results support the idea
that ATX and LPA are active participants in lymphocyte
trafficking, presumably regulating lymphocyte migratory
behaviors locally at HEVs.
Materials and Methods
Mice
C57BL/6J and AKR/J mice were purchased from Japan
SLC (Hamamatsu, Japan) and CLEA Japan (Tokyo, Ja-
pan), respectively. NOD and GFP-transgenic mice18
were kind gifts from Dr. J. Miyazaki (Division of Stem Cell
Regulation Research, Osaka University, Osaka, Japan)
and Dr. M. Okabe (Research Institute of Microbial Dis-
eases, Osaka University), respectively. The following ge-
netically engineered and mutant mice were backcrossed
on a C57BL/6J background for at least four generations,
and the backcrossed progeny were used in experiments
at 6 to 12 weeks of age: CCR7/,19 DOCK2/,20
TLR2/,21 TLR4/,21 MyD88/,21 CXCL13/,22 and
plt/plt.23 Mice were housed at the Institute of Experimen-
tal Animal Sciences at Osaka University Medical School,
and the experimental protocols were approved by the
Ethics Review Committee for Animal Experimentation of
the Osaka University Graduate School of Medicine.
Cells and Reagents
MAdCAM-1 HEV ECs were purified from pooled mes-
enteric LNs as described.24 The mouse capillary EC line,
MBEC425 was maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 2 mmol/L L-glu-
tamine, 100 U/ml penicillin, 100 g/ml streptomycin, 10%
fetal calf serum (FCS), 1 mmol/L sodium pyruvate, 10
mmol/L HEPES, 0.1 mmol/L nonessential amino acids,
and 50 mol/L 2-mercaptoethanol. To establish cells sta-
bly expressing ATX, MBEC4 cells were co-transfected
with a mixture of two plasmids, mlysoPLDpCAGGS26 and
pSV2-neo, carrying the neomycin (G418) resistance
gene, and grown in DMEM containing 750 g/ml of G418
(Sigma, St. Louis, MO). Individual G418-resistant clones
were isolated by limiting dilution and screened by West-
ern blotting and immunocytochemistry with an anti-ATX
mAb (4F1)14 and by measuring the lysoPLD activities of
the culture media. Fatty acid-free bovine serum albumin
(BSA), 1-oleoyl-LPC, and Ki16425 were purchased from
Sigma. LPA (1-oleoyl-2-hydroxy-sn-3-glycerol-3-phos-
phate) was purchased from Biomol International (Ply-
mouth Meeting, PA).
Quantitative Real-Time Reverse Transcriptase-
Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated from various tissues using Isogen
(Nippongene, Toyama, Japan) and reverse-transcribed
using the Super-Script first-strand synthesis system for
RT-PCR (Invitrogen, Carlsbad, CA). Oligonucleotide
primers for PCR were designed using Primer Express
Software (Applied Biosystems, Foster City, CA). The se-
quences of the oligonucleotides used in PCR were as
follows: ATX (mouse), forward, 5-GGAGAATCACACT-
GGGTAGATGATG-3; ATX (mouse), reverse, 5-ACG-
GAGGGCGGACAAAC-3; GAPDH, forward, 5-GCCAA-
GGTCATCCATGACAACT-3; GAPDH, reverse, 5-GAG-
GGGCCATCCACAGTCTT. PCR reactions were per-
formed using an ABI Prism 7000 sequence detection
system (Applied Biosystems). The transcript number of
GAPDH was quantified, and each sample was normal-
ized on the basis of GAPDH content.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections (4 m) were
dewaxed, rehydrated, and boiled in 10 mmol/L citrate
buffer, pH 6.0. Sections were then washed in Tris-buff-
ered saline and incubated with anti-ATX mAb (4F1) and
anti-PNAd mAb (MECA-79)27 or anti-MAdCAM-1 mAb
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(MECA-89)28 at 4°C overnight, followed by biotin-conju-
gated goat anti-rat IgG  IgM (Southern Biotechnology
Associates, Inc., Birmingham, AL). The sections were
further incubated with horseradish peroxidase-conju-
gated ABC reagent (Vectastain ABC-HRP kit; Vector Lab-
oratories, Burlingame, CA), developed with Metal En-
hanced DAB (Pierce, Rockford, IL), and counterstained
with Mayer’s hematoxylin (Muto Pure Chemicals Co., To-
kyo, Japan). In some experiments, biotin-labeled tyra-
mide reagent (Perkin-Elmer Life Sciences, Boston, MA)
was used for signal amplification.
PCR Analysis
Total RNA was extracted from mesenteric LNs using
TRIzol (Invitrogen). Single-strand cDNA synthesized us-
ing the Ready-To-Go kit (GE Health Care UK Ltd., Amer-
sham Place, UK) and a cDNA library of MAdCAM-1
HEVs29 were used in PCR analysis with Ex-TaqDNA poly-
merase (Takara Bio, Otsu, Japan). PCR was performed at
94°C for 2 minutes, 38 cycles at 94°C for 30 seconds, at
57°C for 30 seconds, at 72°C for 30 seconds, and a final
extension at 72°C for 5 minutes. The following primer
pairs were used: ATX: sense, 5-TCTAGCATCCCAGAG-
CACCT-3, antisense, 5-GGTCGGTGAGGAAGGAT-
GAA-3; LPA1: sense, 5-AAGCAAGCATGTGGTGTGTG-
3, antisense, 5-ATGTCTATAGGCATACGTGG-3, LPA2:
sense, 5-GCTAGTACTGAAGCTGATTCC-3, antisense,
5-AGCCTAGTCTATGCGGCAAG-3; LPA3: sense, 5-
GATGAGAGTCCACAGCAACTTG-3, antisense, 5-AG-
ATGCGTACGTATACCGCC-330; and LPA4: sense, 5-
CACATATAAGGATGGAGTCGC-3, antisense, 5-GTCA-
ACTCAACAGAAGAGGC-3; CD3: sense, 5-CCTGA-
CAGCAGTAGCCATAATC-3, antisense, 5-GCTGTTG-
AGTCAGCAATGTCC-3; L-selectin: sense, 5-GCCATG-
GTGTTTCCATGGAGATGTGAGGGT-3, antisense, 5-
ATCATCCATCCTTTCTTGAGATTTCTTGCC-3; -actin:
sense, 5-ATGGATGACGATATCGCT-3, antisense, 5-
ATGAGGTAGTCTGTCAGGT-3. PCR products were an-
alyzed by agarose gel electrophoresis.
In Situ Hybridization Assay
Plasmids (pCRII; Invitrogen) containing cDNA fragments
of LPA1 (500 bp), LPA4 (366 bp), or MAdCAM-1 (482 bp)
were used as templates for RNA probe synthesis. Digoxi-
genin (DIG)-labeled antisense or sense probes were pre-
pared with T7 and SP6 RNA polymerase (Applied Bio-
systems), respectively, using the DIG RNA labeling mix
(Roche Diagnostics, Basel, Switzerland). Mesenteric and
peripheral LNs were fixed with 4% paraformaldehyde for
2 hours, incubated in 30% sucrose in phosphate-buff-
ered saline (PBS) overnight, and embedded in OCT com-
pound. Eight-m-thick serial frozen sections were fixed in
4% paraformaldehyde for 20 minutes, incubated in 0.1%
H2O2, and permeabilized with 50 g/ml proteinase K for
5 minutes. After an additional fixation with paraformalde-
hyde, the sections were treated with acetic anhydride in
triethanolamine for 10 minutes. The sections were then
prehybridized with 50% formamide, 5 standard saline
citrate, 1 mg/ml yeast tRNA (Roche Diagnostics), 100
g/ml heparin, 1 Denhardt’s solution, and 0.1%
Tween 20 at 60°C for 3 hours, and then hybridized with
labeled probe in the same solution overnight at 60°C.
After being washed, the sections were incubated with
horseradish peroxidase-conjugated anti-DIG (Roche
Diagnostics), followed by biotin-labeled tyramide (TSA
Biotin System, PerkinElmer Life Sciences) for signal
amplification. The hybridized probes were then de-
tected by ABC-alkaline phosphatase (Vector Labora-
tories) and NBT/BCIP (Roche Diagnostics).
Fluorescence Microscopy
Purified MAdCAM-1 HEV ECs were seeded in collagen
type 1-coated eight-well culture slides (Becton Dickin-
son, Mountain View, CA) (4  104 cells/well) and incu-
bated for 3 hours in DMEM containing 20% FCS (Hy-
clone, Logan, UT). After the nonadherent cells were
removed, the remaining ECs were treated for 60 minutes
with LPA (15 mol/L) in fresh DMEM containing FCS
stripped with 10% charcoal. Similarly, MBEC4 cells and
ATX-expressing MBEC4 cells were seeded in Lab-Tek II
chamber slides (Nalge Nunc, Rochester, NY) (0.5  104
cells/well), cultured overnight, and treated for 60 minutes
with LPA or LPC (10 mol/L) in fresh DMEM containing
0.1% fatty acid-free BSA. In some experiments, cells
were pretreated with 10 mol/L Ki16425 (Sigma) for 60
minutes at 37°C. After two washes in PBS, the cells were
fixed in 4% paraformaldehyde, permeabilized in PBS
containing 0.1% Triton X-100, and incubated with Alexa
Fluor 594-conjugated MECA89 (2 g/ml) followed by Al-
exa Fluor 488-phalloidin (1 U/ml) (Invitrogen) (for MAd-
CAM-1 HEV ECs) or Alexa Fluor 488-phalloidin alone
(for MBEC4 and ATX-expressing MBEC4 cells). The cells
were then observed under a confocal microscope
(LSM510META; Carl Zeiss, Jena, Germany; or Radiance
2100; Bio-Rad, Hercules, CA) using Fluoromount-G
mounting medium (Southern Biotechnology).
Lymphocyte Binding Assay
Freshly isolated MAdCAM-1 HEV ECs, MBEC4, and
ATX-expressing MBEC4 cells were cultured and stimu-
lated as follows. The MAdCAM-1 HEV ECs were plated
(2.5  104 cells/well) in collagen-coated 96-well plates
(Becton Dickinson) and allowed to adhere for 3 hours in
DMEM containing 20% FCS (Hyclone). After the unbound
cells were removed, the remaining cells were starved for
60 minutes by incubation in DMEM containing 0.1% fatty
acid-free BSA. MBEC4 cells and MBEC4 transfectants
expressing ATX were plated in a flat-bottomed 96-well
plate (1  104 cells/well) and grown in DMEM containing
10% FCS overnight. The cells were then starved for 16
hours by incubation in DMEM with 0.1% fatty acid-free
BSA. These EC preparations were incubated with or with-
out various concentrations of LPA or LPC for 30 to 60
minutes in DMEM with 0.1% fatty acid-free BSA, as indi-
cated. For inhibition studies, the ECs were pretreated
with 10 mol/L Ki16425 for 30 minutes. Spleen cells that
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did not adhere to plastic were labeled with the fluores-
cent indicator BCECF-AM as described,31 in DMEM with
0.1% fatty acid-free BSA. They were then added to the
wells containing the ECs (5  105 cells/well) and al-
lowed to bind to the ECs for 30 minutes under static
conditions or with rotation (120 rpm). Unbound lympho-
cytes were removed by inverting the plate, which had
been filled with prewarmed FCS-free RPMI 1640 and
sealed with Parafilm (Pechinery Plastic Packaging, Inc.,
Menasha, WI) for 30 minutes at room temperature. The
adherent lymphocytes were solubilized with 1% Nonidet
P-40 in PBS, and fluorescence intensity was measured
by a fluorescence enzyme-linked immunosorbent assay
reader (SpectraMax Gemini XS; Molecular Devices,
Sunnyvale, CA).
Short-Term Homing Assay
The lymphocyte migration assay was performed as pre-
viously described.22 Briefly, spleen cells obtained from
GFP-transgenic mice were injected intravenously into
mice (2  107 cell/mouse) that had received an intraperi-
toneal injection of a cocktail of anti-ATX mAbs (clones
5E5, S13A9, and S9A9; 150 g each) or rat IgG (450
g/mouse; Cappel, Aurora, OH) 3 hours before. The mice
were sacrificed 2.5 hours after the lymphocyte injection,
and the spleen, mesenteric LNs, brachial LNs, and PPs
were harvested. The number of lymphocytes that had
migrated into these tissues was determined by flow
cytometry.
LysoPLD Assay
Plasma samples (10 l) were incubated with 4 mmol/L
LPC in buffer containing 100 mmol/L Tris-HCl (pH 9.0),
500 mmol/L NaCl, 5 mmol/L MgCl2, and 0.05% Triton
X-100 for 12 hours at 37°C. The liberated choline was
detected by an enzymatic photometric method using
choline oxidase (Asahi Chemical Industry, Tokyo, Japan),
horseradish peroxidase (Toyobo, Tokyo, Japan), and
TOOS reagent [N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-
toluidine] (Dojin, Tokyo, Japan), as reported previously.32
Absorbance was read at 560 nm and converted to nano-
moles of choline by comparison to a choline standard
curve.
Statistical Analysis
A Student’s t-test was applied to compare the statistical
difference within two groups.
Results
ATX Is Constitutively and Selectively Expressed
in HEVs of Peripheral and Mesenteric LNs
and PPs
Preliminary analysis showed that ATX transcripts ap-
peared at moderate frequencies in the previously gener-
ated 3-directed cDNA libraries of PNAd HEV ECs24
and of MAdCAM-1 HEV ECs33; they appeared five times
among 1558 transcripts obtained from the PNAd HEV
cDNA library and five times among 2101 transcripts in the
MAdCAM-1 HEV cDNA library. Transcripts of endoglin
were found at comparable frequencies in these libraries
(data not shown). ATX transcripts are also found in a
human tonsil cDNA library enriched for HEV-derived
cDNAs by subtraction with lymphocyte cDNAs and um-
bilical vein endothelial cDNAs.16 Real-time PCR analysis
showed that ATX mRNA was strongly expressed in the
peripheral and mesenteric LNs as well as in the brain and
kidney among the mouse tissues tested (Figure 1A).
These findings prompted us to look for the expression
and localization of ATX proteins in HEVs. As shown in
Figure 1B, specific mAb against ATX readily detected its
expression in HEVs of peripheral and mesenteric LNs
and PPs, but not in non-HEV blood vessels in experimen-
tally naïve mice. Although staining intensities varied in
different HEVs, a majority of HEVs of LNs appeared pos-
itive for ATX expression, whereas 30 to 40% of HEVs of
PPs expressed ATX. In mesenteric LNs, both PNAd HEVs
and MAdCAM-1 HEVs expressed ATX (Figure 1C).
We next examined ATX expression in developing LNs.
Although ATX expression was not observed prenatally
(Figure 2A), it was detectable 1 day after birth (Figure
2B), and its level increased progressively until postnatal
day 7 (Figure 2, C and D), concomitant with the increasing
numbers of lymphocytes around HEVs in the peripheral and
mesenteric LNs. The appearance of ATX also paralleled to
that of PNAd in peripheral LNs (data not shown).34
ATX Expression Is Up-Regulated in Venules at
Sites of Chronic Inflammation
HEV-like venules appear in sites other than peripheral
and mesenteric LNs and PPs under certain pathological
conditions. For instance, a marked increase in lympho-
cyte trafficking is associated with the appearance of
HEV-specific adhesion molecules and a HEV-like mor-
phology in the cortico-medullary venules of the thymus in
aged AKR/J mice that develop thymic hyperplasia and
lymphoma.35,36 We found that a majority of the cortico-
medullary venules of hyperplastic thymus from old (30
weeks) AKR/J mice were PNAd, as revealed by mAb
MECA-79 staining, and 60 to 70% of the PNAd
venules were also positive for ATX expression (Figure
3A). Most of the ATX venules appeared PNAd (Figure
3A). In contrast, a majority of the thymic venules of young
AKR/J mice (6 to 8 weeks old) and 30-week-old C57BL/6
mice were PNAd-negative (date not shown), although a
small fraction of C57BL/6 mice (20  30%) showed
weak but distinct ATX expression in these venules at 6 to
8 weeks of age (Figure 3B). A previous study showed that
insulitis in NOD mice is associated with the occurrence of
HEV-like vessels bearing PNAd epitopes.37 Our study
confirmed this observation and showed that a substantial
proportion of the PNAd venules in the pancreas of the
NOD mice were also positive for ATX, whereas the
venules of uninflamed islet tissues in the NOD mice were
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negative for PNAd and ATX (Figure 3C). These observa-
tions are in agreement with the hypothesis that ATX plays
a role in lymphocyte trafficking into chronically inflamed
tissues.
The Expression of ATX Is Independent of
Signals Mediated by Lymphoid Chemokines
(CCL21 and CXCL13), DOCK2, or MyD88
We next addressed the regulatory mechanism of ATX
expression. To this end, we first investigated ATX expres-
sion in the HEVs of CCR7-deficient mice,19 plt/plt mice,23
and CXCL13-deficient mice,22 all of which show substan-
tially reduced lymphocyte homing. In addition, we exam-
ined mice deficient in DOCK-2, which plays an essential
role in CCR7- and CXCR5-mediated signaling20; DOCK-
2-deficient mice also show severely impaired lymphocyte
Figure 1. ATX is selectively expressed in HEVs of LNs and PPs. A: ATX
mRNA expression was examined in various mouse tissues by real-time PCR.
The abundance of ATX mRNA was normalized by GAPDH mRNA control. B:
Serial paraffin sections of peripheral LNs (LN; top), mesenteric LNs (MLN;
middle), and PPs (bottom) from wild-type mice incubated with MECA-79
mAb (left) or anti-ATX/lysoPLD mAb (middle and right). C: Serial sections
of mesenteric LNs incubated with anti-PNAd, anti-ATX, or anti-MAdCAM-1,
and stained as in A. Scale bars 	 100 m.
Figure 2. ATX expression appears in HEVs on day 1 after birth and is
up-regulated subsequently in HEVs. A and B: Serial paraffin sections of
peripheral LNs from neonates on day 0 (A) and day 1 (B) incubated with
anti-ATX mAb or anti-MAdCAM-1 mAb. C and D: Paraffin sections of periph-
eral LNs from day 3 (C) and day 7 (D) stained with anti-ATX mAb as above.
Without anti-ATX mAb, some stromal cells in the developing LNs gave
nonspecific signals. Scale bars 	 100 m.
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trafficking to LNs. All of the mice examined were 6 to 12
weeks old. We saw no differences in ATX expression in
the HEVs of the CCR7-deficient, CXCL13-deficient, plt/
plt, or DOCK-2-deficient mice, compared with wild-type
mice, indicating that lymphocyte trafficking across HEVs
per se does not affect ATX expression in these venules
(Figure 4A). These results also indicate that ATX expres-
sion is independent of lymphoid chemokines, such as
CCL21 and CXCL13, and of CCR7-dependent signals in
the HEVs of adult animals.
Given that HEVs express TLR4 (M. Kiyomi and T.
Tanaka, unpublished observation), which induces a spe-
Figure 3. ATX expression is up-regulated in venules of AKR hyperplastic
thymus and in chronically inflamed blood vessels in the NOD pancreas. A
and B: Serial paraffin sections of hyperplastic thymus from aged AKR/J mice
(A) and thymus of normal mice (B) incubated with anti-PNAd mAb (A: top)
or anti-ATX mAb (A: bottom). In A, the right panel shows a higher
magnification view of the boxed area at left. In B, right panel, boxed region
shows higher magnification view of ATX expression near the cortico-med-
ullary junction in wild-type mouse thymus (indicated by arrow at low
magnification). C: Serial paraffin sections of inflamed (top) and noninflamed
(bottom) pancreas from NOD mice incubated with anti-PNAd mAb or
anti-ATX mAb, as indicated. Scale bars 	 100 m.
Figure 4. The expression of ATX is independent of lymphoid chemokine
(CCL19/21 and CXCL13)-, DOCK2-, or MyD88-mediated signals. Anti-ATX
staining of paraffin sections of mesenteric LNs from CCR7/, CXCL13/,
DOCK2/, or plt/plt mice (A) and TLR4/ or MyD88/ mice (B). Scale
bars 	 100 m.
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cific differentiation program in certain cell types on its
ligation,38 we next examined whether ATX expression is
under the control of TLR signaling. In mice deficient for
TLR4 or MyD88, which mediates signaling by many of the
TLRs,21 there was no noticeable difference from wild-
type in ATX expression (Figure 4B), which is incompatible
with the idea that TLR signaling regulates ATX expression
in HEVs. These results also indicate that innate immunity
signals mediated by TLR4 and MyD88 are dispensable
for ATX expression in HEVs.
HEV ECs Express Specific Receptors for LPA
and Show Cytoskeletal Changes by
LPA Stimulation
Although ATX can generate LPA12,39 and S1P13 from
their respective precursors in vitro, recent studies indi-
cate that ATX is the major LPA-producing enzyme in
vivo.14,40 Therefore, to investigate whether LPA could
act through a paracrine or autocrine mechanism at the
HEV EC surface, we next examined LPA receptor ex-
pression in HEV ECs. We found that MAdCAM-1 HEV
ECs obtained from mesenteric LNs expressed LPA1
and LPA4, and that unfractionated mesenteric LN cells
consisting mainly of lymphocytes expressed readily
detectable levels of LPA1, LPA2, LPA3, and a low level
of LPA4 at the mRNA level (Figure 5A). Importantly, the
possibility that contaminating lymphocytes were re-
sponsible for the expression of the LPA receptors in the
HEV EC preparation was ruled out because the EC
preparation used here showed no signal for CD3 or
L-selectin mRNA, whereas the mesenteric LN cells
showed strong CD3 and L-selectin mRNA signals.
The LPA receptor expression by HEV ECs was also
verified by in situ hybridization analysis. As shown in
Figure 5B, MAdCAM-1-expressing HEV ECs showed
strong signals when hybridized with antisense probes
for LPA1 and LPA4, but not with sense probes for these
receptors. These findings collectively indicate that HEV
ECs express LPA1 and LPA4.
We next examined the function of LPA receptors ex-
pressed by HEV ECs. Given that ATX is constitutively
expressed in HEV ECs, one possible role for this cell-
motility protein is to induce the local production of LPA in
HEVs, which could function in turn as an autocrine or
paracrine factor for the HEV ECs and/or lymphocytes. To
test this possibility, we added LPA to HEV ECs in vitro and
found by confocal imaging that the HEV ECs showed
prominent morphological changes in response to the
exogenous LPA (Figure 5C); 50% of HEV ECs showed
extended cell morphology with actin-rich cell protrusions
and cell-surface ruffling, and this change was almost
completely inhibited by Ki16425, which antagonizes at
least LPA1 and LPA3, if not other isoforms.
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We also examined the effect of LPA and LPC on lym-
phocyte binding to HEV ECs. However, because purified
HEV ECs showed high endogenous lymphocyte binding
in the absence of any deliberate stimulation in vitro,24,33
we could not determine the effect of LPA or LPC on
lymphocyte binding in this experimental setup. Therefore,
to further examine this issue, we resorted to using ATX-
expressing cultured ECs that bind lymphocytes only
moderately.
Forced Expression of ATX by Cultured ECs
Confers Responsiveness to LPC
To generate cultured EC lines constitutively expressing
both ATX and LPA receptors, we introduced an expres-
sion vector for ATX into an EC line, MBEC4, that endog-
Figure 5. HEV ECs express LPA receptors and show cytoskeletal changes in
response to LPA. A: LPA1-4, ATX, CD3, and L-selectin mRNA expression
analyzed by RT-PCR. mRNAs expressed in HEV cDNA libraries (MAdCAM-1
HEVs) and mesenteric LNs were analyzed. -Actin was the positive control.
B: In situ hybridization analysis of LPA1, LPA4, and MAdCAM-1 mRNAs.
Sections of mesenteric LNs were hybridized with DIG-labeled sense or
antisense riboprobes as indicated. C: Adherent HEV ECs, control or stimu-
lated with 15 mol/L LPA, were stained with Alexa Fluor 594-conjugated
MECA89 and Alexa Fluor 488-phalloidin. For inhibition studies, HEV ECs
were pretreated with 10 mol/L Ki16425, an LPA1 and LPA3 antagonist. Scale
bars: 100 m (B); 50 m (C).
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enously expresses receptors for LPA, and determined
the cells’ responses to LPA and LPC. As shown in Figure
6A, the ATX-transfected MBEC4 cell lines (MBEC4-ATX)
expressed ATX abundantly, whereas the parental
MBEC4 ECs did not express ATX. The MBEC4-ATX cells
showed strong morphological changes in response to
LPA and LPC (70% of cells showed extended cell mor-
phology with well-developed stress fibers), and these
Figure 6. LPC induced morphological changes in ATX-expressing ECs and enhanced lymphocyte binding to them.
A: Expression of ATX in MBEC4-ATX cells analyzed by Western blotting. MW, molecular weight. Essentially all
MBEC4-ATX cells (98%) were positive for ATX expression and they produced biologically active ATX with
lysoPLD activity (241.8 nmol/ml/hour in 100-hour conditioned medium). B: MBEC4 or MBEC4-ATX cells incubated
with or without 10 mol/L LPA or LPC were fixed, permeabilized, and stained with Alexa Fluor 488-phalloidin. For
inhibition studies, cells were pretreated with 10 mol/L Ki16425, an LPA1 and LPA3 antagonist. C and D:
MBEC4-ATX and MBEC4 incubated with or without various concentrations of LPA or LPC to which BCECF-labeled
lymphocytes were added without (C) or with continuous rotation (120 rpm) (D). The adherent lymphocytes were
solubilized and quantified by a fluorescence plate reader. For inhibition studies, these cells were pretreated with
Ki16425. Data represent the mean 
 SD for three separate experiments. *, ***P  0.005 compared with vehicle-
treated MBEC4-ATX cells. **, ****P  0.005 compared with vehicle-treated MBEC4 cells.
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changes were inhibited by Ki16425 (Figure 6B). In con-
trast, the parental MBEC4 cell line responded to LPA but
not to LPC. These results are in agreement with the
hypothesis that ECs producing high levels of ATX re-
spond not only to LPA but also to LPC by converting LPC
to LPA, whereas ATX-negative cells respond to LPA but
not to LPC, because they are incapable of hydrolyzing
LPC to LPA.
Differential effects by LPA and LPC on lymphocyte
binding to these EC lines were also observed (Figure 6C).
The MBEC4-ATX cells showed increased lymphocyte
binding when exposed to 1 to 10 mol/L LPA or LPC
under static conditions. In contrast, the MBEC4 cells
showed increased lymphocyte binding in response to 1
to 10 mol/L LPA but not LPC. Under continuous rotation
(120 rpm), the MBEC4-ATX showed increased lympho-
cyte binding in the presence of LPC, whereas the paren-
tal MBEC4 cells did not (Figure 6D). These results further
support the hypothesis that endothelial ATX promotes the
motility of lymphocytes and ECs by converting LPC to
LPA on the EC surface.
Depletion of ATX from the Circulation Does Not
Impair Lymphocyte Trafficking to Secondary
Lymphoid Tissues
ATX is a type-II transmembrane protein that undergoes
membrane-proximal cleavage to yield a soluble lysoPLD
that is released into the plasma.42 To address the func-
tional roles of ATX in regulating lymphocyte trafficking in
vivo, we attempted to deplete the circulating ATX by
injecting a cocktail of anti-ATX mAbs intraperitoneally into
mice. This injection successfully depleted ATX from the
plasma, decreasing the plasma lysoPLD activity to10%
of that seen in mice given a control rat IgG (Figure 7A).
However, lymphocyte trafficking to the spleen, brachial
LNs, mesenteric LNs, and PPs in the anti-ATX-treated
mice, as examined by adoptive transfer of fluorescently
labeled lymphocytes, was comparable to the trafficking
observed in the control mice (Figure 7B). These obser-
vations suggest that the ATX in the general circulation
does not play a major role in lymphocyte trafficking to
secondary lymphoid tissues but argues for the role of
ATX in the local environment; given that ATX is selectively
expressed in HEVs and that endothelial ATX promotes
the motility of lymphocytes and ECs as shown above,
these findings are compatible with the idea that ATX
regulates lymphocyte-endothelial interactions not sys-
temically but locally at HEV.
Discussion
In this study, we addressed the biological role of ATX
expressed by HEVs. ATX expression was abundant in
adult HEVs but scarce in the HEVs of newborns. In the
developing LNs, ATX expression rapidly increased post-
natally in parallel with PNAd expression, and was con-
comitant with the appearance of numerous lymphocytes
around the HEVs. Although not expressed in intact
venules of nonlymphoid tissues, ATX appeared in certain
venules of chronically inflamed tissues, such as the pan-
creatic venules of NOD mice and the thymic venules of
AKR mice, which expressed the L-selectin-reactive PNAd
epitope and showed prominent perivascular lymphocyte
infiltration. In contrast, ATX was absent from blood ves-
sels in these tissues that showed no perivascular lympho-
cyte infiltration. Thus, ATX expression was always posi-
tively correlated with lymphocyte trafficking across
venules, strongly implicating ATX in this phenomenon.
Kanda and colleagues17 recently published a study in
which they showed that ATX, secreted by HEVs, binds to
the chemokine-activated lymphocytes and generated
LPA, which in turn enhances lymphocyte motility through
Gi-coupled receptors. They also showed that intrave-
nous injection of an enzymatically inactive form of ATX
blocked the trafficking of blood lymphocytes to LNs, PPs,
and spleen.17 Our in vitro observations also support a
functional role for ATX in lymphocyte-HEV interactions.
Figure 7. Circulating ATX does not contribute to lymphocyte trafficking to
secondary lymphoid tissues, including spleen, LNs, and PPs. A: Mice were
treated with either control rat IgG (white bar) or anti-ATX mAb (black bar),
and LysoPLD activity in mouse plasma was determined by the liberation of
choline from LPC 5.5 hours after injection of a cocktail of anti-ATX mAbs. B:
Short-term lymphocyte homing assay performed. GFP-expressing mouse
spleen cells were injected intraperitoneally into mice treated with either
control or anti-ATX antibodies 3 hours previously. The numbers of lympho-
cytes that migrated into spleen, mesenteric LNs (MLNs), peripheral LNs
(PLNs), and PPs were quantified by flow cytometry 2.5 hours after the
lymphocyte injection.
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Because ATX is a major producer of LPA,14 we hypoth-
esized that ATX generates LPA from its precursor LPC
and that LPA may act on not only lymphocytes but also
HEV ECs in an autocrine and/or paracrine manner, be-
cause both cells express LPA receptors. Consistent with
this idea, HEV ECs expressed LPA1 and LPA4, and al-
though the effect of LPA and LPC on lymphocyte binding
to HEV ECs could not be determined because of a high
background lymphocyte binding, the HEV ECs showed
increased cell-surface ruffling and pseudopod extension
in response to exogenous LPA, which was abrogated by
Ki16425, indicating that LPA enhances the motility of HEV
ECs, which may facilitate physical encounters and sub-
sequent interactions with lymphocytes in situ. In addition,
when ATX-expressing cultured ECs were used, it was
notable that pretreatment with not only LPA but also LPC
increased the lymphocyte binding to ATX-expressing
ECs under static as well as flow conditions. In contrast,
only LPA (not LPC) increased lymphocyte binding in
ATX-negative ECs. These observations support the idea
that ECs producing high levels of ATX respond to LPA
and also to LPC and that endothelial ATX enhances the
motility of lymphocytes and ECs by converting LPC to
LPA on the HEV EC surface locally. Whether ATX has an
effect on lymphocyte binding to HEVs could be finally
resolved by in situ application of ATX inhibitors, such as
neutralizing anti-ATX monoclonal antibodies, which are
as yet unavailable, to HEVs.
Given that ATX is expressed in restricted cell types in
vivo, its expression must be regulated rigorously. Al-
though transcriptional regulation is likely to be one mech-
anism for this, we do not know what molecules are in-
volved in regulating the transcription of ATX. Our
experiments with mice genetically deficient in CXCL13,
DOCK-2, CCR7, TLR4, or MyD88, and with plt/plt mice,
indicated that neither signals from lymphoid chemokines,
such as CCL21 and CXCL13, nor the TLR4 are involved
in the regulation of ATX expression. Lymphocyte traffick-
ing itself did not appear to be involved in this process
either.
Whereas the above-mentioned results are compatible
with the idea that ATX is involved in the up-regulation of
lymphocyte-HEV interactions by generating LPA locally,
we found that the systemic depletion of ATX did not affect
lymphocyte trafficking into the LNs. This shows a contrast
to the study by Kanda and colleagues17 in which they
showed that enzymatically inactive ATX injected intrave-
nously had an inhibitory effect on short-term lymphocyte
trafficking to lymphoid tissues. This discrepancy might be
at least in part attributable to the fact that the mutant ATX
is much smaller in size and probably penetrates into
tissue parenchyma more readily than antibodies. Given
that ATX is produced by limited cell types in vivo, we
envisage that ATX acts locally at the surface of these
cells, and the circulating level of ATX may be irrelevant to
ATX’s function in vivo. However, because ATX knockout
mice are embryonically lethal,14 we are currently unable
to further assess the in vivo function of ATX at HEVs.
Conditional expression or deletion of ATX in HEV ECs will
be required to answer this issue.
Recent studies have shown that ATX also plays a
critical role for blood vessel formation during develop-
ment.14,40 ATX-deficient embryos show severe vascular
defects and die at midgestation. In the fetal stage, ATX
mRNA is mainly detected in endodermal cells surround-
ing yolk sac and secreted ATX protein accumulates in
amniotic fluid.14 Although ATX and LPA themselves are
not angiogenic in vitro, they can strongly promote blood
vessel formation by stabilizing preformed blood vessels
through currently unknown mechanisms.14 In the adult
stage, we showed that ATX is selectively expressed in
HEV ECs as well as ECs of certain blood vessels in
chronically inflamed tissues. This raises the possibility
that ATX, in addition to stimulating cellular interactions
between lymphocytes and ECs, contributes to the forma-
tion of specialized blood vessels, which support an in-
creased lymphocyte trafficking in LNs and PPs as well as
chronically inflamed tissues by regulating production of
LPA in situ. Mechanisms underlying the selective expres-
sion of ATX in the ECs of certain blood vessels and LPA
receptors responsible for vascular formation remain un-
known. Further study is clearly required to resolve this
issue.
Collectively, these results support the hypothesis that
ATX enhances lymphocyte-HEV interactions in vivo. ATX
may provide another layer of regulation, in addition to that
by lymphoid chemokines, to the trafficking of lympho-
cytes across HEVs. Although it remains to be verified
whether ATX mediates lymphocyte-HEV interactions via
LPA, the future use of specific inhibitors of these mole-
cules, which are not yet available, should finally elucidate
the mode of action of ATX at the HEV-lymphocyte
interface.
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